Breaking News

Xencor Receives Merck Milestone

April 10, 2014

Phase I trial of biologic candidate employs XmAb antibody platform

Xencor, Inc. has received a milestone payment from Merck for the initiation of a Phase I trial for an undisclosed biologic candidate that uses Xencor's XmAb antibody engineering platform.
Under the June 2013 agreement, Xencor granted Merck a non-exclusive license to certain patents for an undiclosed biologic along with an option to license the intellectual property for future products. Xencor receives annual maintenance fees and is eligible to receive success-based milestone payments, as well as royalties on sales of any potential products resulting from this agreement.
"Merck's program is the sixth drug candidate using our XmAb intellectual property currently in clinical trials and is the latest example of our technology offering partners an opportunity to create best-in-class therapeutics," said Bassil Dahiyat, Ph.D., president and chief executive officer of Xencor. "By selectively licensing our XmAb technology, we believe we create value in non-core areas, thus allowing us to focus on advancing our key internal development programs."

Related Contract Manufacturing:

blog comments powered by Disqus
  • Solid Dispersions

    Solid Dispersions

    Robert Harris, Juniper Pharma Services||April 5, 2016
    A universal formulation strategy for poorly soluble drugs?

  • Major Regulatory Changes in China to Impact Western Drug Developers

    Major Regulatory Changes in China to Impact Western Drug Developers

    David Deere, PaizaBio||January 28, 2016
    PaizaBio reports on drug development and manufacturing strategies

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.